Data for this review were identified by searches of Medline and references from relevant articles; numerous articles were identified through searches of the authors'extensive files. Search terms were “Mycobacterium avium complex”, “Thrapy”, “prophylaxis”, “clinical trials”, “guidelines”, “human immunodeficiency virus”, “acquired immunodeficiency syndrome”, “highly active antiretroviral-drug therapy”, “macrolides”, “clarithromycin”, “azithromycin”, “rifabutin”, “fluoroquinolones”, and
ReviewMycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy
Section snippets
Clinical features and the effect of HAART
Soon after inhalation or ingestion of MAC organisms from the environment, the infection spreads via local lymphatics, eventually disseminating haematogenously.8 The bacteria are taken up by mononuclear phagocytic cells throughout the body, and reticuloendothelial organs such as the liver, spleen, and bone marrow are the most frequently affected sites.8 Consequently, the clinical presentation of disseminated MAC commonly includes fever, weight loss, night sweats, fatigue, diarrhoea,
Prophylaxis Criteria for initiating primary prophylaxis
Before the development of effective chemoprophylaxis, up to 40% of HIV-infected patients developed disseminated MAC within 2 years of the diagnosis of AIDS.1, 2 HIV-infected adults who have a CD4 cell count of less than 50 cells/mL are at heightened risk for MAC infection and should receive chemoprophylaxis (table 2).18 Although official guidelines do not include criteria for prophylaxis on the basis of HIV plasma RNA (viral load) measurements, it seems that patients with high viral loads are
Regimens
Rifabutin, a semi-synthetic rifamycin with substantial activity against MAC in vitro and in animal models,21, 22 was the first drug found to have some benefit in preventing MAC infection in patients with AIDS.23 Two multicentre, randomised, double-blind, placebo-controlled trials showed that rifabutin (300 mg daily) prophylaxis significantly reduced the rate of MAC bacteraemia from 17–18% to 8–9% in patients with AIDS.23 Additionally, rifabutin prophylaxis was associated with a significant
Discontinuation of primary prophylaxis
Because of concerns about potential incomplete restoration of immunological function in patients whose CD4 cell count rose significantly in response to antiretroviral therapy,36 earlier guidelines recommended indefinite continuation of primary prophylaxis for MAC infection.37 Subsequent studies have investigated the safety of discontinuing primary chemoprophylaxis against MAC in patients whose CD4 cell counts, in response to HAART, have risen above threshold values for the initiation of
Treatment
A major advance in the treatment for disseminated MAC was the recognition of the in-vivo efficacy of clarithromycin, which is now regarded as the cornerstone of any potent regimen.40, 41 ACTG 157 was a randomised, double-blind, dose-ranging study in HIV-infected patients with MAC bacteraemia who were assigned to three different dosage regimens of clarithromycin (500, 1000, and 2000 mg twice daily) for 12 weeks.40 Time to clearance of bacteraemia was faster at higher doses but was equivalent in
Future directions
Significant progress has been made in the last decade in the treatment of HIV and in the prevention and treatment of various opportunistic infections, including MAC. These advances have resulted in a diminished rate of MAC infection in developed countries. However, MAC continues to occur frequently in areas of the world where HAART is unavailable, or in patients who do not have access to or who cannot tolerate HAART, or who have developed drugresistant HIV infection. For these patients, MAC
Search strategy and selection criteria
References (69)
- et al.
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group
Lancet
(1998) - et al.
Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group
Lancet
(1999) - et al.
Phase III, randomized, doubleblind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis
Clin Ther
(2000) - et al.
Phase III, randomized, doubleblind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis
Clin Ther
(2000) - et al.
Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine
J Infect
(2002) - et al.
Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency viruspositive patients
J Infect Dis
(1992) - et al.
Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group
Am Rev Respir Dis
(1992) - et al.
Natural history of disseminated Mycobacterium avium complex infection in AIDS
J Infect Dis
(1991) - et al.
The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients: a prospective study
J Infect Dis
(1994) - et al.
Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy
Am Rev Respir Dis
(1991)
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
N Engl J Med
Epidemiology of human immunodeficiency virusassociated opportunistic infections in the United States in the era of highly active antiretroviral therapy
Clin Infect Dis
The pathophysiology of disseminated Mycobacterium avium complex disease in AIDS
J Infect Dis
Early manifestations of disseminated Mycobacterium avium complex disease: a prospective evaluation
J Infect Dis
Clinical and laboratory findings of disseminated Mycobacterium avium complex infection (DMAC) in a pair matched case-control study
Rev Inst Med Trop Sao Paulo
Clinical features and outcome in disseminated mycobacterial diseases in AIDS patients in Taiwan
AIDS
Natural history of opportunistic disease in an HIV-infected urban clinical cohort
Ann Intern Med
Impact of opportunistic disease on survival in patients with HIV infection
AIDS
The incidence and spectrum of AIDS-defining illnesses persons treated with antiretroviral drugs
Clin Infect Dis
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study
BMJ
A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome
Clin Infect Dis
Guidelines for preventing opportunistic infections among HIVinfected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America
MMWR Recomm Rep
Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents
AIDS
Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections
AIDS
Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods
Antimicrob Agents Chemother
In vivo activities of newer rifamycin analogs against Mycobacterium avium infection
Antimicrob Agents Chemother
Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS
N Engl J Med
Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS
AIDS
Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis
N Engl J Med
Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebocontrolled multicenter trial
Clin Infect Dis
Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group
N Engl J Med
Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease
Clin Infect Dis
Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution
Antimicrob Agents Chemother
A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome
N Engl J Med
Cited by (177)
Nontuberculous Mycobacterial Pulmonary Disease in the Immunocompromised Host
2023, Clinics in Chest MedicineAntimicrobial susceptibility of Mycobacterium abscessus and treatment of pulmonary and extra-pulmonary infections
2023, Clinical Microbiology and InfectionCarbohydrate-based drugs launched during 2000−2021
2022, Acta Pharmaceutica Sinica BPatterns of Mycobacterium avium-intracellulare complex infection in duodenal endoscopic biopsies in HIV/AIDS patients
2020, Annals of Diagnostic PathologyRole of fluorescence in situ hybridization in detecting mycobacterium avium complex presenting as fever in treatment failure HIV
2020, Journal of Clinical Tuberculosis and Other Mycobacterial DiseasesCitation Excerpt :Night sweats, diarrhoea, nausea and vomiting, and abdominal pain have also been reported [1,4]. Laboratory tests may show anaemia and elevated levels of alkaline phosphatase and lactate dehydrogenase [1,5]. A rise in SGOT, SGPT was reported in this case, which could be part of granulomatous hepatitis due to disseminated MAC infection.